Manage & Schedule One on One Meetings
This year, the [15th World ADC San Diego] will be returning with One-on-One Partnering™! In [October], registered event attendees will be able to set up their company profile, update their calendar availability, and start requesting and accepting meetings.
Key Dates:
[Monday, October 7]
One-on-One Partnering opens for registered attendees
[Monday, October 14]
One-on-One Partnering scheduling begins
What To Expect
The [15th World ADC San Diego Summit] will offer all registered attendees access to One-on-One Partnering™, a tool for managing and pre-scheduling one-on-one meetings:
Find the Right Partners
Leverage our powerful search feature to find companies, delegates, assets, and markets for products or services. It’s a detailed catalogue of the most up-to-date partnering data, enabling you to find the best opportunities
Schedule Face-to-Face Meetings
Find the best times for your meetings and gain efficiency with automatic reminders and follow-up emails. Schedule meetings for all attendees whether they are physically present or not thanks to our hybrid capabilities.
Leverage Your Meeting
The history of your company's meetings at conferences hosted on One-on-One Partnering™ is at your fingertips. Know when you last met with a company, who attended and what messages were exchanged with our data archiving capabilities.
Collaborate with Colleagues
Work seamlessly as one team. View and modify your colleagues’ schedule, add them to meetings and share notes.
Explore the Agenda
Discover the target selection, drug design and preclinical strategies to identify differentiated targets, optimize next-generation radiopharmaceuticals and build the evidence needed to progress towards the clinic.
Partner With Us
Position your expertise in front of 100+ discovery and preclinical RLT leaders actively seeking technologies, services and specialist partners across target discovery, drug design, imaging, radiochemistry, preclinical development, dosimetry, and safety.
Join RLT Experts
Join 100+ radiochemists, biologists, drug designers, and R&D leaders advancing next-generation radioligand therapies from discovery through translation.